"10.1371_journal.pone.0144901","plos one","2016-01-06T00:00:00Z","Nathaniel Z Piety; Xiaoxi Yang; Julie Kanter; Seth M Vignes; Alex George; Sergey S Shevkoplyas","Department of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America; Sickle Cell Center of Southern Louisiana, Tulane University School of Medicine, New Orleans, Louisiana, United States of America; Department of Pediatrics, Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, United States of America","Conceived and designed the experiments: SSS. Performed the experiments: NZP XY SMV. Analyzed the data: NZP XY SSS. Contributed reagents/materials/analysis tools: SSS. Wrote the paper: NZP XY JK SMV AG SSS. Designed the software used in analysis: NZP. Wrote the clinical protocols, obtained IRB approvals, and enrolled patients: JK AG.","SSS, NZP, XY and JK are inventors on a utility PCT application Paper based diagnostic test (PCT/US2012/064856, 11/13/2012) claiming priority benefit of US 61/692,994 (8/24/2012) and US 61/558,009 (11/10/2011). SSS is a part-owner of Halcyon Biomedical Incorporated, a company that may benefit from commercialization of the paper-based SCA test. XY is an employee of BioMedomics, Inc., developer of the Sickle SCANâ„¢ test. JK is a consultant to BioMedomics, Inc. and to Daktari Diagnostics, Inc., developer of the density-based SCD-AMPS diagnostic test. SMV and AG declare no potential conflicts of interest. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","01","Nathaniel Z Piety","NZP",6,TRUE,1,3,3,6,TRUE,TRUE,FALSE,0,NA,FALSE
